Literature DB >> 10951582

Immuno-histochemical detection of human telomerase reverse transcriptase in human liver tissues.

Y Kawakami1, M Kitamoto, T Nakanishi, W Yasui, E Tahara, J Nakayama, F Ishikawa, H Tahara, T Ide, G Kajiyama.   

Abstract

Although telomerase activity in hepatocellular carcinoma (HCC) increases in accordance with degree of histological undifferentiation, it is unknown whether the level of telomerase activity in HCC reflects of the degree of activity in individual cells or the frequency of telomerase-positive HCC cells. Non-cancerous liver tissues exhibit low but significant levels of telomerase activity, but the nature of telomerase-positive cells in these tissues is unclear. In this study, we performed immunohistochemical staining using specific antibody against telomerase reverse transcriptase (hTERT) protein in 15 HCC samples and 13 adjacent non-cancerous liver tissues. There were hTERT-positive hepatocytes, though very low frequency, in non-cancerous liver tissues. The frequencies in hTERT positive hepatocytes were very well correlated with clinicopathological parameters and telomerase activity levels: the average frequencies of chronic hepatitis was 0.2%, liver cirrhosis 0.2%, well-differentiated HCC 3.0%, moderately differentiated HCC 28%, and poorly differentiated HCC 95%. The intensity of staining varied among cells within a given specimen, and correlation with degree of histological undifferentiation was less obvious. Portions of migrating lymphocytes and biliary epithelial cells were also hTERT-positive. These findings indicate that the upregulation of telomerase activity with degree of undifferentiation of HCC is mainly due to the increase in frequency of hTERT positive HCC cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951582     DOI: 10.1038/sj.onc.1203733

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Nuclear telomerase is less accessible to antibody probing than known nuclear antigens: retrieval with new immunostaining buffer.

Authors:  Danny Tze-Ming Leung; Chun-Hung Ma; Haitao Niu; Choong-Tsek Liew; Janet Tsui-Ying Tang; Pak-Leong Lim
Journal:  Histochem Cell Biol       Date:  2004-11-05       Impact factor: 4.304

Review 2.  Stem cell therapy for inherited metabolic disorders of the liver.

Authors:  Susan Ellor; Thomas Shupe; Bryon Petersen
Journal:  Exp Hematol       Date:  2008-04-02       Impact factor: 3.084

3.  Expression of human telomerase reverse transcriptase in thyroid follicular neoplasms: an immunohistochemical study.

Authors:  Sheng-Lan Wang; Wan-Tzu Chen; Ming-Tsang Wu; Hon-Man Chan; Sheau-Fang Yang; Chee-Yin Chai
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

4.  Telomerase inhibition and telomere loss in BEL-7404 human hepatoma cells treated with doxorubicin.

Authors:  Ru-Gang Zhang; Li-Xia Guo; Xing-Wang Wang; Hong Xie
Journal:  World J Gastroenterol       Date:  2002-10       Impact factor: 5.742

Review 5.  Treatment of Liver Cancer.

Authors:  Chun-Yu Liu; Kuen-Feng Chen; Pei-Jer Chen
Journal:  Cold Spring Harb Perspect Med       Date:  2015-07-17       Impact factor: 6.915

6.  HCV core inhibits hepatocellular carcinoma cell replicative senescence through downregulating microRNA-138 expression.

Authors:  Tzu-Yue Shiu; Yu-Lueng Shih; An-Chieh Feng; Hsuan-Hwai Lin; Shih-Ming Huang; Tien-Yu Huang; Chung-Bao Hsieh; Wei-Kuo Chang; Tsai-Yuan Hsieh
Journal:  J Mol Med (Berl)       Date:  2017-03-03       Impact factor: 4.599

7.  Expression profile of a gamma-deletion variant of the human telomerase reverse transcriptase gene.

Authors:  Hisashi Hisatomi; Kazuma Ohyashiki; Junko H Ohyashiki; Kumi Nagao; Taichi Kanamaru; Hiroyuki Hirata; Nozomu Hibi; Yutaka Tsukada
Journal:  Neoplasia       Date:  2003 May-Jun       Impact factor: 5.715

8.  Significance of immunological detection of human telomerase reverse transcriptase: re-evaluation of expression and localization of human telomerase reverse transcriptase.

Authors:  Satoru Kyo; Kenkichi Masutomi; Yoshiko Maida; Taro Kanaya; Noriyuki Yatabe; Mitsuhiro Nakamura; Masaaki Tanaka; Mitsuko Takarada; Isamu Sugawara; Seishi Murakami; Takahiro Taira; Masaki Inoue
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

Review 9.  Current systemic treatment of hepatocellular carcinoma: A review of the literature.

Authors:  Kai-Wen Chen; Tzu-Ming Ou; Chin-Wen Hsu; Chi-Ting Horng; Ching-Chang Lee; Yuh-Yuan Tsai; Chi-Chang Tsai; Yi-Sheng Liou; Chen-Chieh Yang; Chao-Wen Hsueh; Wu-Hsien Kuo
Journal:  World J Hepatol       Date:  2015-06-08

Review 10.  HCV Proteins Modulate the Host Cell miRNA Expression Contributing to Hepatitis C Pathogenesis and Hepatocellular Carcinoma Development.

Authors:  Devis Pascut; Minh Hoang; Nhu N Q Nguyen; Muhammad Yogi Pratama; Claudio Tiribelli
Journal:  Cancers (Basel)       Date:  2021-05-19       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.